)
Zymeworks (ZYME) investor relations material
Zymeworks Jefferies Global Healthcare Conference 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Leadership and company overview
Newly appointed Chief Business Officer highlighted the company's strong R&D innovation and robust financial position, emphasizing a dual business model: internal R&D and external partnerships.
The company manages a portfolio of wholly owned and partnered assets, focusing on oncology and immunology.
Zanidatamab (Zani) updates and outlook
Zanidatamab demonstrated statistically significant survival benefit in frontline gastric cancer, with broad efficacy across PD-L1 subgroups.
Priority review for sBLA with PDUFA date set for August 25, with expectations for robust global adoption.
Expansion opportunities include the EmpowHER-303 breast cancer trial, with top-line readout expected late 2027 or early 2028.
Early data suggest potential benefit in post-Enhertu settings due to Zani’s unique mechanism.
ZW191 (Folate receptor alpha ADC) progress
ZW191 shows strong activity and tolerability in early data, with dose optimization cohorts fully enrolled and about 60 patients in expansion.
Data from expansion expected at ESMO GYN, focusing on folate expression subgroups and dose response.
Preclinical data support potential for combination therapies due to favorable tolerability profile.
- Annual meeting to vote on directors, executive pay, auditor, and highlight ESG and governance.ZYME
Proxy filing18 May 2026 - Key votes include director elections, executive pay, and auditor ratification at the 2024 meeting.ZYME
Proxy filing18 May 2026 - Board recommends approval of all proposals, with strong focus on governance and performance-based pay.ZYME
Proxy filing18 May 2026 - Q3 revenue up 73% on milestone and royalty gains, with narrowed net loss and strong cash runway.ZYME
Q3 202518 May 2026 - Virtual annual meeting on Dec 30, 2025, covers director elections, pay, and auditor ratification.ZYME
Proxy filing18 May 2026 - FDA Priority Review, $250M royalty loan, and robust pipeline drive long-term value.ZYME
Q1 202618 May 2026 - Robust pipeline advances and strong cash position drive a royalty-focused growth strategy.ZYME
The Citizens Life Sciences Conference 202615 May 2026 - Hybrid biotech-royalty model, strong pipeline, and $250M financing drive growth and flexibility.ZYME
TD Cowen 46th Annual Health Care Conference28 Apr 2026 - Strong financials and innovation drive growth, with key catalysts and pipeline advances ahead.ZYME
2026 Bloom Burton & Co. Healthcare Investor Conference21 Apr 2026
Next Zymeworks earnings date
Next Zymeworks earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)